Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1997-6-19
|
| pubmed:abstractText |
The population pharmacokinetics of atovaquone were examined in 458 black, Oriental, and Malay patients with acute Plasmodium falciparum malaria receiving atovaquone alone or concomitantly with other drugs. Oral clearance (CL/F) showed a 0.674 power relationship with weight and is similar in Oriental and Malay subjects but 58.5% lower in black subjects. On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively. The relationship between apparent volume of distribution (V area/F) and weight was linear and similar in all three races at 7.98 L/kg. The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively. The bioavailability of the high and low doses of atovaquone was similar. Neither CL/F nor V area/F were significantly affected by age, gender, and the coadministration with chloroguanide (proguanil), pyrimethamine, and tetracycline. Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively. The final magnitudes of interpatient variability in CL/F and V area/F were 68% and 49%, respectively.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0009-9236
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
61
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
518-30
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9164414-Adolescent,
pubmed-meshheading:9164414-Adult,
pubmed-meshheading:9164414-Analysis of Variance,
pubmed-meshheading:9164414-Antimalarials,
pubmed-meshheading:9164414-Atovaquone,
pubmed-meshheading:9164414-Child,
pubmed-meshheading:9164414-Child, Preschool,
pubmed-meshheading:9164414-Computer Simulation,
pubmed-meshheading:9164414-Databases, Factual,
pubmed-meshheading:9164414-Dose-Response Relationship, Drug,
pubmed-meshheading:9164414-Female,
pubmed-meshheading:9164414-Gabon,
pubmed-meshheading:9164414-Humans,
pubmed-meshheading:9164414-Kenya,
pubmed-meshheading:9164414-Malaria, Falciparum,
pubmed-meshheading:9164414-Male,
pubmed-meshheading:9164414-Middle Aged,
pubmed-meshheading:9164414-Models, Biological,
pubmed-meshheading:9164414-Naphthoquinones,
pubmed-meshheading:9164414-Philippines,
pubmed-meshheading:9164414-Thailand,
pubmed-meshheading:9164414-Zambia
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.
|
| pubmed:affiliation |
Glaxo Wellcome, Beckenham, and Pharmaceutical Systems Inc., Talent, Oregon, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|